Hannah Clarke

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

The RAPID-III trial will assess outcomes with flexible cystoscopy with or without the FloStent implant deployed.

"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.

Data from the SOUND trial are intended to support submission for FDA 510(k) clearance of the Break Wave device.

View slated interviews with experts as well as insights from urologists on what to watch for.

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025.

The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.

We preview several noteworthy P2 presentations in the urologic oncology space.

The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.

Overall, 71% of patients had no fragment greater than 2 mm following treatment.

There is also a need to improve multidisciplinary care, according to Ekene Enemchukwu, MD.

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.

Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.

Ian Metzler, MD, discusses developments in imaging and treating stones.

Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.

The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.

“Given the rates in epidemiologic studies and surveys showing that up to 70% of women are symptomatic, we were surprised to find that only 9% [filled] a prescription,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.

"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.

Sima P. Porten, MD, MPH, discusses the need to better understand how genetic makeup influences how individuals process environmental toxins.

“I think it will help patients decide what prostate surgery they want,” says Naeem Bhojani, MD, FRCSC.

“The technology in the field of stone management is exciting, and I think it offers patients a lot more options than what they've had in the past,” says Brian Stork, MD.

An approach to WVTT involving 1 treatment per prostate lobe was associated with decreased post-operative complications.

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, MPH, FACS, URPS.